Navigation Links
Optimer Pharmaceuticals to Present at the Canaccord Genuity Annual Growth Conference
Date:8/1/2011

SAN DIEGO, Aug. 1, 2011 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) today announced that the Company will present at the Canaccord Genuity Annual Growth Conference on August 10, 2011 at 11:30 a.m. Eastern Time at the InterContinental Hotel in Boston.

(Logo:  http://photos.prnewswire.com/prnh/20090413/LA97352LOGO)

A live audio webcast of this presentation will be accessible in the Investors section of the Company's website at www.optimerpharma.com. Replays of this presentation will be available at the same location for 30 days following the meeting.

About Optimer Pharmaceuticals

Optimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing innovative hospital specialty products that have a positive impact on society. Optimer developed and is commercializing DIFICID™ (fidaxomicin) Tablets, an FDA approved antibacterial drug for the treatment of adult patients with Clostridium difficile-associated diarrhea (CDAD). Optimer has filed a marketing authorization application with the European Medicines Agency for fidaxomicin. Optimer's clinical pipeline includes Pruvel™, a product in the fluoroquinolone class of antibiotics that has completed Phase 3 trials as a treatment for infectious diarrhea. Additional information can be found at http://www.optimerpharma.com.

Contacts:
Optimer Pharmaceuticals, Inc.
David Walsey, Vice President, Investor Relations and Corporate Communications
858-909-0736

Canale Communications, Inc.
Jason I. Spark, Senior Vice President
619-849-6005


'/>"/>
SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Optimer Pharmaceuticals and Clinical Investigators to Present Data at Upcoming Medical Meetings
2. Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
3. Optimer Pharmaceuticals, Inc. Announces Exercise in Full of Underwriters Option to Purchase Additional Shares and Closing of Public Offering of Common Stock
4. Optimer Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
5. Optimer Pharmaceuticals to Present at Oppenheimer Healthcare Conference
6. Optimer Pharmaceuticals Announces Presentations at Upcoming IDSA Annual Meeting
7. Optimer Announces Presentation of Additional Data from Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection (CDI) Presented at ICAAC
8. Optimer Pharmaceuticals Phase 3 Clinical Trials show Fidaxomicin is Superior to Vancomycin in Treatment of Recurrent Clostridium difficile Infection (CDI); Data Presented at ICAAC
9. Optimer Pharmaceuticals Reports Third Quarter 2009 Financial Results
10. Optimer Pharmaceuticals to Present at September 2009 Investor Conferences
11. Optimer Pharmaceuticals Announces Presentations of Additional Phase 3 Fidaxomicin and Prulifloxacin Data at Upcoming ICAAC Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... August 21, 2014 His Majesty Willem-Alexander, ... , The Court of His Majesty Willem-Alexander, King of ... the Grand Opening of POET-DSM Advanced Biofuels’ Project LIBERTY ... 3. , The King will take part in the ... scheduled for 11 a.m.-12:20 p.m. and tour the plant. ...
(Date:8/21/2014)... , Aug. 21, 2014 OTC ... Pharmaceuticals Inc., a biotechnology company, on its approval ... previously traded on OTCQX®, the best marketplace for ... Markets Group. Logo - http://photos.prnewswire.com/prnh/20110118/MM31963LOGO ... the successful execution of its growth strategy and ...
(Date:8/21/2014)... Gallus BioPharmaceuticals , LLC, ... manufacturing organization (CMO) announced today that it has ... company focused on the development of innovative approaches ... anti-prostate specific membrane antigen (PSMA) monoclonal antibody used ... the agreement the antibody will be produced in ...
(Date:8/20/2014)... Grade school history lessons often have it that American ... whooping cough, chicken pox, influenza and tuberculosis brought to ... while estimates vary, about 20 million people lived in ... percent of them were killed by European diseases., But ... Arizona State University and Johannes Krause of the University ...
Breaking Biology Technology:His Majesty Willem-Alexander, King of the Netherlands, to Attend Project LIBERTY opening 2His Majesty Willem-Alexander, King of the Netherlands, to Attend Project LIBERTY opening 3OTC Markets Group Congratulates Immune Pharmaceuticals on NASDAQ Listing 2Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 2Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 3Unusual discovery leads to fascinating tuberculosis theory 2Unusual discovery leads to fascinating tuberculosis theory 3
... RATON, Fla., Feb. 17, 2011 Sensus ... participation in the 9th Annual South Beach ... 17-21, 2011.  The South Beach Symposium™ is a comprehensive ... and practice management. Sensus Healthcare is featuring superficial radiotherapy ...
... of Santiago de Compostela (USC) have analysed levels of radon, ... The results show that 34% of these schools exceed the ... inhalation of radon is associated with lung cancer. "Out ... had radon levels in excess of 400 Bequerels/m3 in some ...
... a significant component of the defense system of many ... armies and terrorist organizations, and constitute a threat to ... solutions against them have limited efficiency. A multidisciplinary ... succeeded in developing an enzyme that breaks down such ...
Cached Biology Technology:Sensus Healthcare Announces Its Exhibitor Attendance at the 9th Annual South Beach Symposium™ 234 percent of Galician secondary schools exceed maximum recommended radon levels 2Weizmann Institute scientists used accelerated evolution to develop enzymes that provide protection against nerve gas 2Weizmann Institute scientists used accelerated evolution to develop enzymes that provide protection against nerve gas 3Weizmann Institute scientists used accelerated evolution to develop enzymes that provide protection against nerve gas 4
(Date:8/21/2014)... implications for life in other extreme environments, both on ... Associate Professor of Biological Sciences Brent Christner and fellow ... this week published a paper confirming that the waters ... (2600 feet) beneath the surface of the West Antarctic ... than 400 subglacial lakes and numerous rivers and streams ...
(Date:8/21/2014)... to Wednesday, Oct. 18-22, 2014 , WHERE: ... Drive, San Diego, CA 92101 , WHAT: ... presentations of the latest research in human genetics. ... featuring high-scoring abstracts on rare genetic variants in ... and treatment for sun sensitivity (Saturday, Oct. 18, ...
(Date:8/21/2014)... researchers at Louisiana Tech University has developed ... 3D printers and materials to fabricate custom ... chemotherapeutic compounds for targeted drug delivery. , ... research faculty from Louisiana Tech,s biomedical engineering ... filament extruders that can make medical-quality 3D ...
Breaking Biology News(10 mins):800 meters beneath Antarctic ice sheet, subglacial lake holds viable microbial ecosystems 2800 meters beneath Antarctic ice sheet, subglacial lake holds viable microbial ecosystems 3800 meters beneath Antarctic ice sheet, subglacial lake holds viable microbial ecosystems 4American Society of Human Genetics 2014 Annual Meeting 2Louisiana Tech University researchers use 3D printers to create custom medical implants 2Louisiana Tech University researchers use 3D printers to create custom medical implants 3
... Washington, D.C. -- Disease statistics buried within patient ... and organized to depict geographic patterns, allowing the discovery ... Penn State geographer. "The use of interactive maps ... to greater insight into complex events like the spread ...
... region has a hot, wet climate and a lot of ... a really good chance the region will also contain numerous ... study examining the geography of human disease, led by Dr. ... team of biologists and social scientists, shows that that one ...
... world-wide project "MAGICPAH", coordinated by the Braunschweiger Helmholtz-Zentrums ... Braunschweig- HZI), is examining how bacterial communities are ... aromatic hydrocarbons. "MAGICPAH" is a collaboration of thirteen ... enterprises have initiated the project today at the ...
Cached Biology News:Visualization of geographic patterns may predict spread of disease 2Study pins factors behind geography of human disease 2Study pins factors behind geography of human disease 3Improving the degradation of toxic hydrocarbons 2
... The Beacon 2000 Fluorescence Polarization System ... research and assay development. Standard Beacon ... 2000 System uses a quartz-halogen lamp ... of 360-700 nm. It accommodates all ...
... traps a wide variety of solvent vapors that ... glass condensation flask (GCF400) allows for the collection ... easy draining. Rapid cooling time minimizes waiting period., ... quick solvent changes , -50?C ...
... Phosphatase-2A (PPase-2A) is a serine/threonine phosphatase isolated ... isolated as the heterodimer of 60kDa (A) ... ability to dephosphorylate the a-subunit of phosphorylase ... has broad substrate specificity and may play ...
... Varioskan is a high performance spectral ... and incubator. With the advanced SkanIt ... reliability for drug discovery assay development. ... fluorescence intensity, time-resolved fluorescence and photometric ...
Biology Products: